TIL Therapy Yakafumurwa: Kuongorora Iyo Landscape yeCancer Immunotherapy
Chii chinonzi Tils Therapy?
TILs kurapa kunosanganisira kubvisa tumor-infiltrating lymphocytes (TILs), ari chaiwo echisikigo anti-bundu immune masero mumuviri wemurwere, kubva mubundu nekuarima muhuwandu hukuru murabhoritari. Aya maTIL akabatiswa anobva adzoserwa mumuviri wemurwere kuti atsigise simba rekudzivirira muviri kunanga nekuuraya maseru egomarara. MaTIL anoshanda nekuziva chaiwo mamaki pamaseru egomarara uye nekutanga mhinduro yekuzvidzivirira kubva pavari, zvichizotungamira mukuparadza bundu.
Ndeipi nzira yeTils Therapy?
Clinical mhedzisiro yeTils Therapy
Zvichienderana nemigumisiro yedu yekurapa kwekiriniki, kushanda kwese kweTILs monotherapy kunosvika kusvika ku40%, zvichiita kuti ive nzira yekurapa bundu inonyanya kushanda kunze kwekuvhiyiwa ikozvino. Imwe kana akati wandei marapirwo achasanganiswa neTils therapy, iyo inozowedzera chiyero chinoshanda kusvika kupfuura 80%. Iyo yakasanganiswa kurapa ine chinangwa chekudzikisa bundu remunguva pfupi, uye tils inopa mukana wekuti murwere apore mukufamba kwenguva.
Zvakanakira Tils Therapy
High specificity:bundu chairo T masero anonzwisiswa ne tumor antigens, anozivikanwa neakawanda TCRs
Strong tropism:kutaura kwepamusoro kwechemokine receptors, yakasimba tumor tropism, uye nekukurumidza kuita
Kuuraya mapundu:TILs dzinoitwa uye dzinokwidziridzwa kusvika 109-1011, uye masero ekenza asara anocheneswa mushure mekuvhiyiwa.
Kuenderera mberi:Chikamu chendangariro T masero chakakwira, uye anogona kurarama mumuviri kwenguva yakareba uye achiramba achitariswa.
Kuchengetedzwa kwepamusoro:kudhirowa, kukwidziridzwa, hapana kurambwa kuita, uye SAE yeTILs masero kubva kuvarwere ivo pachavo
Zviratidzo zveTils Therapy
Tils therapy yakaratidza kushanda mukatiNSCLC (isiri diki sero remapapu cancer),Melanoma, kenza yemazamu,Cervical Cancer,uye Ovarian Cancer.
Ndeapi matishu anogona kushandiswa kubvisa TILs?
Kunze kwekuvhiya kubviswa kwebundu rekutanga, chepamusoro tumor tissue, lymph nodes, pleural effusion, ascites, nezvimwewo, zvinogonawo kuedzwa kubviswa. Kubudirira kwepamusoro ndekunotevera: primary lesion ≥ metastatic lesion ≥ lymph nodes ≥ ascites.
Varwere vese vanogona kubudirira kurima maTIL?
Yedu yakazvimiririra yakagadziridzwa maTILs kurima maitiro anowana budiriro ye ≥85%. Iine yakajairwa tishu sampuro ye ≥1cm3, mabhiriyoni eTIL anogona kurima, uye maseru anoratidza yakasimba cytotoxic chiitiko."
Migumisiro yeTILs therapy?
1.TILs ndiwo masero omurwere, saka hapana ngozi yekurambwa, kuve nechokwadi chekuchengetedzwa kwepamusoro.
2. Kuita kwakashata: Fivha inowanzoitika (nekuda kwekusunungurwa kwema cytokines panguva yeTILs cell-mediated tumor clearance, zvichiita kuti fivha inopera, kazhinji isingadi kurapwa kwakananga uye kugadzirisa pachayo).
3.Kumwe kukanganisa kwakashata kunotaurwa mune zvidzidzo zvinosanganisira thrombocytopenia, febrile neutropenia, hypertension, nezvimwewo, zvakanyanya kunzi kune TILs pamwe chete nemimwe mishonga yakadai sepre-treatment chemotherapy (cyclophosphamide + fluorouracil), high-dose IL-2, PD-1 monoclonal antibodies, nezvimwewo.
tsananguro2